Leukocytes and coronary heart disease

Hoffman, Michael A.; Blum, Arnon; Baruch, Roni; Kaplan, Ervin; Benjamin, Moshe

doi:10.1016/s0021-9150(03)00164-3

Cited by 199 publications

(161 citation statements)

References 55 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Similar changes in adiponectin levels during rosiglitazone treatment have been observed in patients with impaired glucose tolerance (23), type 2 diabetes (24, 50) and in one non-placebo-controlled study in women with PCOS (13). In a previous study, we demonstrated that the well-known risk factors for coronary heart disease and type 2 diabetes, serum levels of CRP and white blood cell count (51)(52)(53)(54)(55), decreased during rosiglitazone treatment (Rautio et al in press). Thus, the present findings further support a beneficial effect of rosiglitazone on metabolic and cardiovascular risk factors in PCOS.…”

Section: Discussionmentioning

confidence: 89%

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

Majuri¹,

Santaniemi²,

Rautio³

et al. 2007

eur j endocrinol

View full text Add to dashboard Cite

Objective: Abdominal obesity, insulin resistance and compensatory hyperinsulinaemia play a central role in the pathogenesis of the polycystic ovary syndrome (PCOS). Abdominal adipose tissue is a source of adipokines, such as adiponectin and resistin, both of which may be involved in the development of insulin resistance and chronic inflammation in PCOS. Ghrelin, an important regulatory peptide of food intake, may also play a role in metabolic disturbances related to PCOS.The aim of this study was to examine the effects of 4 months of treatment with the insulin sensitizer rosiglitazone on plasma adiponectin, resistin and ghrelin levels in overweight women with PCOS. Design: A randomised placebo-controlled study. Methods: Thirty overweight/obese women with PCOS (body mass indexO25 kg/m 2 , mean age 29.1G 1.2 (S.E.M.) years) were randomly allocated to either rosiglitazone (Avandia, 4 mg twice a day) or placebo treatment. Plasma levels of adiponectin, resistin and ghrelin and their correlation to serum levels of insulin, C-peptide and steroid hormones, and insulin sensitivity (euglycaemic hyperinsulinaemic clamp) were assessed. Results: Adiponectin and ghrelin levels correlated significantly with most metabolic markers of insulin resistance and with serum levels of DHEA and 17-hydroxyprogesterone. Plasma levels of adiponectin increased from 9.26G0.90 (S.E.M.) to 22.22G3.66 mg/ml (P!0.001) and those of resistin decreased from 12.57G1.63 to 9.21G0.53 ng/ml (PZ0.009) at 4 months of treatment, but plasma ghrelin levels did not change. Conclusions: Rosiglitazone had beneficial effects on serum levels of adiponectin and resistin, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during the treatment.

show abstract

Section: Discussionmentioning

confidence: 89%

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

Majuri¹,

Santaniemi²,

Rautio³

et al. 2007

eur j endocrinol

View full text Add to dashboard Cite

show abstract

“…Leukocyte count is a simple, inexpensive and well-standardized biomarker of acute or chronic inflammation [2]. Some epidemiologic studies [2][3][4][5] have demonstrated that high leukocyte count is an independent risk factor for future coronary heart disease (CHD). Only few prospective studies [6][7] examined the association between leukocyte count and incidence of stroke.…”

Section: Introductionmentioning

confidence: 99%

Leukocyte count is associated with incidence of coronary events, but not with stroke: A prospective cohort study

Engström

Hedblad

2010

Atherosclerosis

View full text Add to dashboard Cite

ObjectiveElevated leukocyte count is a classic marker of systemic inflammation. This study examined whether the leukocyte count is associated with incidence of coronary events (CE) and stroke during a long follow-up period. MethodsA total of 17,131 men and 2,932 women, aged 27-61 years, without history of cardiovascular disease (CVD), were enrolled. Incidence of CE and stroke was studied in relation to leukocyte concentrations over a mean follow-up of 24 years. ResultsDuring the follow-up period, 2,600 CE and 1,333 stroke events occurred. After risk factor adjustments, leukocyte concentrations in the highest quartile (vs. lowest, >7.0 vs. <4.7 x10 9 cells/L) was associated with CE in men (HR: 1.31, 95%CI: 1.16-1.48, trend p<0.001), but not significantly in women (HR: 1.46, CI: 0.87-2.46, trend p=0.13). The increased incidence remained significant after adjustments for plasma fibrinogen in a subgroup of 6,018 men (HR: 1.31 CI: 1.08-1.60).The association between leukocytes and CE was most pronounced in younger men (aged 27-46) and men without hypertension. In younger men, high leukocytes were associated with early CE (within 10 years of follow-up) and late CE (>10 years of follow-up). In older men (46-61 years), leukocytes were not associated with CE after more than 10 years of follow-up.The leukocyte count was not associated with incidence of stroke. 3 ConclusionElevated leukocyte count in men is associated with incidence of CE, but not with incidence of stroke. The increased risk persisted after more than ten years of follow-up in younger, but not in older men.

show abstract

“…Moreover, it has been found that the significant rise in the levels of inflammatory markers in ACS helps in prediction of future cardiovascular risk (14). For instance, it has been claimed that monocyte procoagulant activity stimulated by IL-6 can cause an association between inflammation and thrombosis in patients with CAD (15). But in our study, we did not find such an association when we assessed the infection seropositivity and acute inflammatory response in the acute stages in patients referring with suspected ACS.…”

Section: Discussionmentioning

confidence: 99%

Association of Severity of Coronary Lesion with Markers of Acute Infection and Inflammation in Patients with Acute Coronary Syndrome

Koçak¹,

Harmankaya²,

Erdemir³

et al. 2017

EAJEM

View full text Add to dashboard Cite

Leukocytes and coronary heart disease

Cited by 199 publications

References 55 publications

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

Leukocyte count is associated with incidence of coronary events, but not with stroke: A prospective cohort study

Association of Severity of Coronary Lesion with Markers of Acute Infection and Inflammation in Patients with Acute Coronary Syndrome

Contact Info

Product

Resources

About